ASH 2020 | BFCR4350A: a novel bispecific antibody in R/R myeloma therapy
Simon Harrison, MBBS MRCP (UK) PhD FRCPath (UK) FRACP, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia, discusses GO39775, an ongoing Phase I trial (NCT03275103) evaluating the safety and efficacy of BFCR4350A monotherapy in patients with relapsed/refractory (R/R) multiple myeloma. BFCR4350A is a novel bispecific antibody that targets the most membrane-proximal domain of FcRH5 on myeloma cells and CD3 on T-cells. Encouraging initial data was found, with patients exhibiting high response rates. The study continues to explore ways of mitigating treatment-emergent adverse effects and improving the overall safety profile of BFCR4350A. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
